Next-generation orthobiologics could transform spinal fusion by enabling targeted bone regeneration, improving safety, and reducing reliance on traditional grafts and hardware.
- Delivery Device Functional Scrutiny: Can You Pass (Without) The Test?
- Red Blood Cell-Based Delivery: Promising Steps Forward
- Stability And Release Testing For Delivery Devices: Waived Or Wanted?
- Microneedles In Drug Delivery: From Bench To Patch
- How Targeted Nanoparticles And Circular RNA Are Advancing CAR-T Development
- Beyond The Surface: Balancing Efficacy, Safety, And Patient Experience In Ophthalmic Delivery
- Enhancing Gene And Cell Therapies With Circular RNA-Based Gene Expression
- Biomaterials In Ophthalmology Are Reshaping Ocular Drug Delivery
ON-DEMAND WEBINARS
Explore how traditional and innovative pharmaceutical packaging formats improve patient adherence, support emerging therapies, and shape the future of drug delivery and treatment outcomes.
Optimize drug delivery by leveraging advanced nanoparticle engineering to dramatically increase small-molecule oral drug loading and enable ultra-high-concentration subcutaneous formulations.
Using volatile processing aids to increase drug solubility in more environmentally friendly solvents, like methanol, reduces the amount of solvent required to manufacture amorphous solid dispersions (ASDs).
Learn how advanced containment solutions support high-viscosity biologics, improve device compatibility, enhance injection performance, and address evolving drug delivery and patient care challenges.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![AST- ASEPTiCell ScreenShot 16]( "The Future Of CDMOs: Aseptic Filling Solutions For Growth And Innovation")
The Future Of CDMOs: Aseptic Filling Solutions For Growth And InnovationThe rapid rise of highly targeted cell and gene treatments requiring small batch production necessitates a new path forward for biologics manufacturing and directly impacts the CMO/CDMO landscape.
-
![West-BIO 1 - 88_NovaPureSyringes_0922]( "Achieving EU GMP Annex 1 Compliance For Contamination Control")
Achieving EU GMP Annex 1 Compliance For Contamination ControlGain insight into three areas that have been key in ensuring a robust contamination control strategy to help ensure compliance with the updated Annex 1 regulation: planning, people, and products.
-
![GettyImages-1435081495-Self-Injector_Auto-Injector]( "Autoinjectors: A Revolutionary Leap In Drug Delivery")
Autoinjectors: A Revolutionary Leap In Drug DeliveryExplore how the widespread adoption of autoinjectors is transforming the biopharmaceutical industry's approach to drug delivery, offering precise dosing, patient adherence, and safety.
-
![Keys To Driving Consistent Quality In Contract Manufacturing]( "Keys To Driving Consistent Quality In Contract Manufacturing")
Keys To Driving Consistent Quality In Contract ManufacturingComplex products and supply chains present plenty of opportunities for failure, especially when new products are being developed and launched. This article discusses key ingredients to robust and advanced quality planning that are essential to quality in contract manufacturing.
-
![West3]( "Taking A Best Practice Approach To Contamination Control")
Taking A Best Practice Approach To Contamination ControlImplementing the EU GMP Annex 1 requires a holistic, evolutionary Contamination Control Strategy built on standardization, data analytics, and continuous improvement for a zero-defect mindset.
-
![GettyImages-1087218944 Scientists In Sterile Suits Working With Computers In The Laboratory]( "Meet Regulation Requirements With RTU Vials And Cartridges")
Meet Regulation Requirements With RTU Vials And CartridgesSterile manufacturing remains vital, with resilient supply chains preventing shortages. Industry and regulators prioritize integrity as demand surges, making it the fastest-growing pharmaceutical segment.
-
![iStock-1087218874]( "Improved Biomanufacturing Processes And Drug Product Stability")
Improved Biomanufacturing Processes And Drug Product StabilityImprove upstream media for bioavailability and foam stability, downstream buffers for purification, and the formulation and final fill drug product stability with this highly interdisciplinary process.
-
![US-EU-flag-3D-GettyImages-94920629]( "Effects Of Annex 1 Revisions On Manufacturing Operations")
Effects Of Annex 1 Revisions On Manufacturing OperationsThe revisions to EU Annex 1 set the stage for the future direction of the pharma/biotech industry. Explore some of the key takeaways and interesting changes for risk management and contamination control strategies.
-
![West-Vol 8-Blog]( "FAQs On The Revised EU GMP Annex 1: Volume 8")
FAQs On The Revised EU GMP Annex 1: Volume 8Successfully implementing a site-wide CCS requires prioritizing barrier technologies, integrating primary packaging into risk assessments, and adopting a data-driven approach to environmental monitoring.
-
![Reducing Costs And Improving Adherence For Self-Administration Of New Biologics]( "Reduce Costs And Improve Adherence For Self-Administration Of Biologics")
Reduce Costs And Improve Adherence For Self-Administration Of BiologicsThere is a growing trend toward wearable injectors for bolus delivery in order to help improve adherence and lower the costs of therapy.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
Fran offers keen industry and technical insights exclusively on Drug Delivery Leader.
DELIVERED BY DEGRAZIO
-
![Delivered _by _DeGrazio_Logo_Color_2]( "Procuring Packaging And Delivery Systems: Single Versus Dual Sourcing")
Procuring Packaging And Delivery Systems: Single Versus Dual SourcingIn this article, Fran DeGrazio examines the trend toward dual sourcing of products, components, and materials for drug delivery packaging and systems. She outlines the key differences between single and dual sourcing and makes recommendations about using one versus the other while mitigating supply chain and product quality risk.
FREE EBOOK: COMBINATION PRODUCTS
Combination products provide significant avenues for increasing patient adherence and overall efficacy. This collection outlines the opportunity and identifies strategies for gaining regulatory approval.
